Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Immunogenicity of the Novel RNA Tumor Vaccine Targeting MICA/B Stress Proteins in Patients With Advanced Solid Tumors

NCT06610227 is registered in ClinicalTrials.gov with NING LI as lead sponsor.

NCT NCT06610227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06610227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Immunogenicity of the Novel RNA Tumor Vaccine Targeting MICA/B Stress Proteins in Patients With Advanced Solid Tumors
Lead sponsor
NING LI
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 8, 2024
Completion date
December 1, 2025
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors